FDA's TEMPO pilot added Limbic, Cadence & Dexcom, letting digital health firms skip premarket authorization in exchange for post-market data reporting to CMS.
The FDA has been quietly selecting participants for its TEMPO pilot. A third, the behavioral health company Limbic, was just added to the pilot’s webpage …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The FDA named Dexcom its first TEMPO participant, allowing digital health devices to reach Medicare patients before authorisation…
The Food and Drug Administration (FDA) is tapping Limbic, the maker of an AI-led behavioral health tool, as an early participant…
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Under the TEMPO pilot program, Dexcom can receive Medicare reimbursement when seniors receive care from their software.
Insulet’s wearable insulin patch Omnipod may be able to seamlessly control insulin delivery for patients with diabetes, but it…
FDA's CBER chief outlines a pilot to fast-track Phase 1 trials, pairing sponsors with vetted research institutions; applications…
